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ABSTRACT 
Aldehyde dehydrogenase (ALDH) is a key enzyme of alcohol metabolism, 
removing acetaldehyde which is formed as a product of the alcohol dehydrogenase 
reaction. If acetaldehyde is not effectively removed, acetaldehyde accumulates 
and produces an adverse reaction to alcohol, with nausea, flushing and increased 
heart rate and blood pressure. 
ALDH is involved in the conversion of retinal to retinoic acid (RA). RA has 
recently been shown to bind to receptors, which then act as nuclear transcription 
factors and play important roles in foetal development and maintenance of the 
epithelial layer in the body. Interference by ethanol and perhaps by acetaldehyde 
with this process is probably the cause of Foetal Alcohol Syndrome. 
In addition ALDH is also involved in the metabolism of catecholamine 
neurotransmitters, plays a role in the removal of toxic substances from the body 
and may have a role in protection against some chemical carcinogens. 
Dr. Kerrie Jones had obtained moderate levels of expression of recombinant 
ALDH in E. coli and constructed a number of mutants chosen on the basis of 
chemical modification data and sequence alignment. Mutant proteins were also 
expressed and assayed for enzyme activity in crude extracts. 
The aim of this thesis was to improve purification and yield of the expressed 
ALDH proteins. By the use of site-directed mutagenesis I attempted to mutate the 
amino acid residue Lys272 to either alanine, histidine or arginine. Future 
comparison of the properties of the site-directed mutants with those of the wild 
type enzyme will help to determine the importance of the residue (which has been 
replaced by mutagenesis) to catalysis. 
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Chapter One 
Introduction 
2 
1.1 OVERVIEW 
Aldehyde dehydrogenase (E.C. 1.2.1.3) is an important enzyme in the pathway of 
alcohol metabolism and may be involved in the regulation of alcoholic drinking 
behaviour ( see section 1.5 .1 ). It also plays a more general protective role in the 
removal of toxic substances from the body and is involved in the conversion of 
retinol to retinoic acid. 
Retinoic acid (RA) has been shown to bind nuclear receptors, which then act as 
nuclear transcription factors and play important roles in foetal development and in 
the maintenance of many tissues. Interference by ethanol and perhaps by 
acetaldehyde with this process, is probably the cause of Foetal Alcohol Syndrome 
(see section 1.5.2). Aldehyde dehydrogenase (ALDH) may play a role in 
protection against some chemical carcinogens but it has also been implicated in 
resistance to cytophosphamide anti cancer drugs (see section 1.5.3). 
ALDH catalyses the NAD(Pt dependent irreversible oxidation of vanous 
aldehyde substrates to their corresponding acids. It exhibits a fairly broad 
substrate specificity with aldehydes of a variety of structures, including straight 
chain and branched, aliphatic and aromatic aldehydes being oxidised. ALDH 
primary endogenous substrates have yet to be identified and therefore the 
biological roles of ALDH are not clear. It seems likely that a particular form of 
ALDH may be able to oxidise efficiently a number of aldehyde substrates, the 
exact substrate varying with tissue and/or physiological situation. 
ALDH was first isolated by Racker (1949) from bovine liver. In the late 1960s 
and during the 1970s ALDH was isolated from various other microbial and 
mammalian sources (see section 1.2). Research has since been directed towards 
identifying its physiological roles and understanding the structure and function 
relationships of the enzyme. 
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1.2 LOCALISATION OF ALDEHYDE DEHYDROGENASE 
1.2.1 Isolation of aldehyde dehydrogenase 
ALDH isozymes have been found in a variety of sites in the bodies of mammals, 
reflecting its role in the oxidation of aldehydes arising from other metabolic 
processes as well as those due to alcohol consumption. The highest levels of 
ALDH are found in the liver, which corresponds to the main site of ethanol 
oxidation in the body. 
ALDH was first isolated by Racker (1949) from bovine liver. ALDHs from yeast 
(Steinman & Jakoby, 1967) and Pseudomonas aeruginosa (Tigerstrom & Razzell, 
1968) were isolated and purified in 1967 and 1968, but these two non-mammalian 
ALDHs exhibit significantly different properties from those found in mammals. 
ALDH has now been isolated and purified to homogeneity from a number of 
mammalian sources including horse liver (Feldman &Weiner, 1972; Eckfeldt & 
Yonetani, 1976), bovine liver (Sugimoto et al., 1976; Leicht et al., 1978), rat liver 
(Shum & Blair, 1972; Tottmar et al., 1973), rabbit liver (Duncan, 1977), sheep 
liver (Crow et al., 1974; MacGibbon et al., 1979; Hart & Dickinson, 1977) and 
human liver (Greenfield & Pietruszko, 1977; Kraemer & Dietrich, 1968). 
1.2.2 Tissue and subcellular distribution 
Liver possesses the highest ALDH activity (Tottmar et al., 1973; Crow et al., 
1974; Horton & Barrett, 1975; Siew et al., 1976; Marjanen, 1972; Dickinson & 
Berrieman, 1979; Tipton et al., 1981, 1989; Lindahl, 1979). A variety of isozyme 
forms of ALDH have been identified in the mitochondrial, microsomal and 
cytosolic fractions. Human liver contains multiple ALDHs distributed 
approximately equally between mitochondria and cytosol. Forms with both high 
and low-~ values for substrate are known and different ALDH forms may have 
different substrate preferences. The low-~ mitochondrial and high-~ cytosolic 
4 
forms account for the majority of the acetaldehyde oxidising capacity of the 
human liver. A human microsomal ALDH has also been identified (Helander & 
Tottmar, 1986; Koivula, 1975; Santisteban et al., 1985; Tipton et al., 1989). 
In all species examined tissues other than liver also possess significant ALDH 
activity (Deitrich, 1966; Simpson & Lindahl, 1979; Holmes, 1978; Rout & 
Holmes, 1985; Manthey et al., 1990; Remond & Cohen, 1971; Petersen et al., 
1977; Smolen et al., 1981; Harada et al., 1978, 1980; Duley et al., 1985; Yoshida, 
1990; Santiseban et al., 1985; Seeley et al., 1984; Holmes & VandeBerg, 1986; 
Nilsson, 1988, 1989). For example, brain and kidney possess significant ALDH 
activity and the subcellular distribution and characteristics of these isozymes are 
generally similar to those of liver (Holmes, 1978; Rout & Holmes, 1985; Harada 
et al., 1978; Holmes & VandeBerg, 1986; Cox et al., 1975; Cederbaum & Rubin, 
1977; Hjelle et al., 1983; Erwin & Deitrich, 1966; Pettersson & Tottmar, 1982; 
Inoue & Lindros, 1982). 
Other tissues, most notably cornea, lung, stomach and urinary bladder have a 
different subcellular distribution and activity profile from those of the liver 
(Manthey et al., 1990; Dunn et al., 1988; Evces and Lindahl, 1989; Lindahl, 1986; 
Teng, 1981; Yin et al., 1989; Messiha, 1982). In these tissues the cytosol 
possesses most of the ALDH activity. In the cornea more than 90% of the total 
ALDH activity is cytosolic (Holmes & VandeBerg, 1986; Evces & Lindahl, 1989; 
Lindahl, 1986; Teng, 1981; Yin et al., 1989; Messiha, 1982), where in stomach 
and urinary bladder the contribution of the cytosol to total ALDH approaches 50% 
(Remond & Cohen, 1971; Lindahl, 1986). 
The distribution of the three classes of ALDH among mammalian tissues is 
complex. All tissues probably possess mitochondrial ALDH. However 
depending on the tissue and species they may also possess a constitutive cytosolic 
ALDH. In addition for some tissues other cytosolic forms of ALDH can be 
induced under certain conditions. 
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1.3 CLASSIFICATION 
1.3.1 High-Km and low-Km aldehyde dehydrogenase groups 
Eight different ALDH gene products have been identified from human DNA (Hsu 
et al., 1995; Lin et al., 1996). The best studied isozymes are the cytosolic and 
mitochondrial forms, ALDHl and ALDH2 respectively (Greenfield & Pietruszko, 
1977). 
On the basis of the Michaelis constants for acetaldehyde the human ALDH forms 
can be divided into high-¾ (millimolar range) and low-Km (micromolar range) 
groups, as proposed by Tottmar et al. (1973). The low-Km forms comprise of 
ALDHl , ALDH2 and y-aminobutyraldehyde dehydrogenase (Greenfield & 
Pietruszko, 1977; Kurys et al. , 1989). Human ALDH3 and ALDH4 (Yin et al., 
1989; Forte-McRobbie & Pietruszko, 1986) and rat microsomal ALDH (Lindahl 
& Evces, 1984) are the high-~, forms. 
The low-¾ mitochondrial and high-~, constitutive cytosolic forms account for 
the majority of the acetaldehyde oxidising capacity of the human liver (Kraemer 
et al., 1968; Blair et al., 1969; Feldman & Weiner, 1972; Crow et al., 1974; 
Eckfeldt & Yonetani, 1976; Eckfeldt et al., 1976; Sugimoto et al. , 1976; 
Greenfield & Pietruszko, 1977). 
1.3.2 Aldehyde dehydrogenase classes 
ALDHs can be divided into five different classes based on the primary structure 
relationships of the various isozymes (Lindahl and Hempel, 1991). Class 1 
(constitutive cytosolic) and class 2 (mitochondrial) share around 67% amino acid 
sequence identity and are homotetramers of 55 kDa monomer size (Hempel & 
Jomvall, 1989; Yoshida et al., 1991). Class 3 ALDH inducible forms of the 
enzyme (e.g. microsomal, stomach cytosolic and tumour-specific) are homodimers 
with 50 kDa monomer size and show less than 30% amino acid sequence identity 
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with classes 1 and 2 (Jones et al., 1988; Hsu et al., 1991; Hempel et al., 1989). 
Other isozymes classified as class 4 and ALDHx have also been reported (for 
review, see Yoshida et al., 1991). 
1.4 ALDEHYDE DEHYDROGENASE STRUCTURE 
At the time of the research component of this thesis little was known about the 
tertiary structure of the ALDH, although basic similarities had been shown to exist 
among various mammalian sources of ALDH. It was known that the class 1 and 
class 2 ALDH isozymes functioned as tetramer enzymes of approximately 
220,000 to 250,000 Dalton's and that each isozyme was composed of identical 
subunits each containing approximately 500 amino acids. However the 
coenzyme-binding area known to be present in dehydrogenases, could not be 
identified from the primary structure. 
After the completion of the experimental work reported in this thesis the tertiary 
structures of the class 2 and class 3 ALDH enzymes were published (Steinmetz et 
al., 1997; Sun et al., 1995). Studies on the bovine liver class 2 isozyme by 
Steinmetz et al. (1997) observed that each subunit within the tetramer was 
composed of three distinct domains; two dinucleotide-binding domains and a 
small three-stranded P-sheet domain involved in subunit interactions in the 
enzyme. Although a recognisable Rossmann-type fold was also found, the 
coenzyme binding region of class 2 ALDH bound NAD+ in a manner that had not 
been seen in other NAD+ binding enzymes (Steinmetz et al., 1997). 
The structure of recombinant rat liver class 3 ALDH was resolved by Sun et al. 
(1995). This isozyme was found to be a dimeric rather than a tetrameric 
quaternary structure. It is composed of two sub-domains connected by a peptide 
hinge with the N terminal domain being somewhat larger than the C-terminal 
domain. The two monomers associate in the dimer in a head to tail manner (Sun 
et al., 1995). 
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1.5 METABOLISM 
1.5.1 Alcohol metabolism 
Studies on the regulation of ethanol metabolism in mammalian liver have shown 
that the activity of alcohol dehydrogenase (ADH) is an important regulatory factor 
(Braggins & Crow, 1981; Crow & Hardman, 1989; Page et al., 1991). ALDH 
probably plays a secondary regulatory role and the balance of activities between 
ADH and ALDH regulates the concentration of acetaldehyde in the liver (Crow et 
al., 1982; Page et al., 1991). 
Because alcoholism is a significant health problem, major efforts have been made 
at understanding ethanol metabolism in the hope of gaining some insight into the 
pathophysiology of this widespread disease. The development of a clear 
understanding of the reaction mechanism of ALDH may be of use in the treatment 
of alcoholism. 
As previously mentioned ALDH is an important enzyme in the pathway of alcohol 
metabolism, where it catalyses the oxidation of acetaldehyde in the liver to form 
acetate. As acetaldehyde is reactive and toxic, increased blood acetaldehyde 
levels are responsible for the symptoms of acute alcohol poisoning (i.e. flushing, 
headache and nausea) and for chronic damage to many organs, particularly the 
liver (Truitt and Walsh, 1971). 
Acetaldehyde is thought to increase collagen gene transcription by binding to 
proteins that usually act as repressors, thereby causing de-repression of the gene 
and excessive collagen synthesis and deposition (Brenner & Chokier, 1987; 
Niemela et al., 1990). This may be the first step in the development of alcoholic 
liver damage. 
1.5.1.1 
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Alcohol flush reaction 
Although there are multiple forms of ALDH in the liver, class 2 ALDH is 
believed to be responsible for the oxidation of most acetaldehyde generated during 
alcohol metabolism. Many Orientals and some South American Indians lack this 
mitochondrial ALDH activity and hence their ability to metabolise alcohol 1s 
impaired because acetaldehyde is degraded slowly and therefore accumulates. 
The alcohol-flush reaction resulting from excessive acetaldehyde accumulation is 
believed to cause physiological responses unpleasant enough to serve as a 
deterrent to further drinking in both disulfiram-treated patients and in individuals 
who have inherited the atypical mutant allele of ALDH-1 (Dyck, 1990). 
1.5.2 Foetal Alcohol Syndrome 
Foetal Alcohol Syndrome (F.A.S.) consists of a varied group of neonatal 
malformations including brain, craniofacial, limb and growth abnormalities that 
are the result of excessive maternal ethanol consumption (Streissguth et al., 1980). 
Despite numerous studies designed to research ethanol embryotoxicity in humans, 
rodents and other vertebrates, no single underlying mechanism for the teratogenic 
action of ethanol has been proposed (Schenkner et al., 1990; Randall et al., 1990). 
Recent studies on the molecular basis of vertebrate embryonic development have 
revealed that RA plays a major role in the specification of spatial patterns during 
the morphogenesis of nervous system and limb tissues, both of which show 
abnormalities in cases ofF.A.S. The controlled conversion of vitamin A into RA 
by specific embryonic tissues has been proposed as a major regulatory step in the 
morphogenic process (Duester, 1991; Durston et al., 1989; Wagner et al., 1990; 
Maden et al., 1990). 
One important aspect of RA induced differentiation that is not understood is the 
mechanism regulating the synthesis of RA from retinol (vitamin A). In mammals 
retinol in the liver or other tissues can be converted to RA via a two step oxidation 
9 
in which ADH (the rate limiting step) produces retinal and ALDH produces RA 
(Leo et al., 1989; Napoli, 1986). Studies indicate that RA can also induce ADH 
gene expression suggesting a positive feedback mechanism for controlling RA 
synthesis (Duester, 1991). 
Ethanol, a typical class 1 ADH substrate, acts as a competitive inhibitor of retinol 
oxidation in human liver extracts (Mezey & Holt, 1971) and it was proposed by 
Deuster et al. (1991) that a connection between F.A.S., RA homeostasis and 
ethanol-retinol metabolism catalysed by human ADH. 
1.5.3 Lipid peroxidation and tumour cells 
Peroxidation of lipids is a continuous process that can be stimulated by a number 
of factors that induce cellular oxidative stress. The reactions involved in lipid 
peroxidation are complex and a wide variety of products can be formed. Among 
the stable products of lipid peroxidation are a variety of aldehydes which 
comprise the majority of molecules produced from peroxidation of either linoleic 
or arachidonic acid (Canuto et al., 1994). 
Changes in the activities of enzymes metabolising aldehydes produced during 
lipid peroxidation have been reported in tumour cells. Consistent increases in 
ALDH and aldehyde reductase activities relative to normal liver have been 
reported in both primary hepatocellular carcinomas and hepatoma cell lines. It is 
well established that many types of tumour cells have a reduced lipid peroxidation 
capacity compared to their normal counterparts (Canuto et al., 1994). 
Class 3 ALDH is induced by a number of chemical carcinogens and this is also 
found in high levels in some tumours (Campbell et al., 1989; Canuto et al., 1989; 
Quemener et al., 1990). The metabolic significance of these observations are not 
clear, but the enzyme may play a role in protection against some chemical 
carcinogens (Lindahl, 1992). 
1.5.3.1 
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Cancer treatment 
The presence of enzymes which metabolise and inactivate alkylating agents in 
tumour and normal cells, appear to play a major role in determining the 
effectiveness of using alkylating agents against human tumours and the toxicities 
of these agents to normal tissues. ALDH appears to protect bone marrow and the 
gastrointestinal tract against toxicity from cyclophosphamide and other closely 
related oxazophorine agents. 
The resistance to the cyclophosphamide anti-cancer drugs demonstrated by one 
type of bone marrow tumour cells has been shown to be due to high levels of 
ALDH (Colvin et al., 1988). If ALDH could be selectively activated in normal 
tissue cells as opposed to tumour cells, it would be a great advantage in cancer 
treatment (Colvin et al., 1988; Kastan et al., 1991; Koelling et al., 1990). 
1.5.4 Biogenic amines 
Although ALDH is generally considered to function in detoxication, Ambroziak 
& Pietruszko (1991) suggest that it has an additional function in metabolism of 
biogenic aldehydes arising from biogenic amines and polyamines (Erwin & 
Dietrich, 1966; Ambroziak & Pietruszko, 1991). 
In the brain the metabolism of biogenic amines is an important role. Among the 
biogenic amines found in the brain, high polyamine concentrations are found in 
brain tumour tissues and a correlation between the brain and the activity of 
enzymes involved in the polyamine pathway has been demonstrated. A 
relationship between alterations in ALDH isozyme activities and cytosolic 
aldehyde concentrations with respect to normal or tumour cell growth has been 
suggested by Quemener et al. (1990). 
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1.6 KINETIC STUDIES 
Extensive studies of the kinetics of cytoplasmic ALDH have been carried out 
(MacGibbon et al., 1977a,b,c, 1978b; Bennett et al., 1982, 1983; Blackwell et al. , 
1985; Hart & Dickinson, 1978a, 1982, 1983; Hart et al., 1982; Dickinson, 1985; 
Buckley & Dunn, 1982, 1985). MacGibbon et al. (1977a,b,c) demonstrated that 
the enzyme operates by an ordered mechanism with NAD+ binding before 
aldehyde. The steady state appears to be at least partially controlled by the rate of 
dissociation ofNADH from the binary E.NADH complex. 
From stopped-flow studies of the enzyme-catalysed reaction, Bennett et al. (1982) 
showed that a conformational change of the enzyme, which follows aldehyde 
binding (with simultaneous release of a proton), is rate limiting in the pre-steady-
state phase of the reaction. 
1.7 CHEMICAL MODIFICATION STUDIES 
Chemical modification of ALDH that leads to activation has also been 
investigated (Kitson, 1979, 1982a, b, 1986; Loomes & Kitson, 1989). The actions 
of disulfiram and related drugs have recently been reviewed (Kitson, 1989; 
Peachey, 1989). p-Nitrophenyl dimethylcarbamate was used to identify cysteine 
302 as the active site nucleophile in the esterase action of cytosolic ALDH (Kitson 
et al., 1991). 
Class 1 ALDH is very sensitive to disulfiram in vitro and it is likely that the use of 
this drug causes significant inhibition of the enzyme in vivo (Kitson, 1989). 
Evidence suggests however that the mitochondrial isozyme is responsible for 
much of the acetaldehyde oxidation during ethanol metabolism in vivo. Therefore 
a question remains as to which isozyme is responsible for the 'disulfiram-ethanol 
reaction' (Kitson, 1989). Inhibition of the cytosolic enzyme may also be the cause 
of some of the unwanted side-effects of disulfiram, due to inhibition of natural 
substrates. 
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Modification of ALDH with iodoacetamide results in the labelling of cysteine 302 
(Hempel et al., 1985). Pre-exposure of ALDH to disulfiram decreased the rate of 
reaction with iodoacetamide, supporting the idea that iodoacetamide modifies a 
group at or near the active site. This conclusion was supported by the work ofvon 
Bahr-Lindstrom et al. (1985) and Kitson et al. (1991) who labelled cysteine 302 
with the esterase substrate analogue 4-nitrophenyl dimethylcarbamate. Blatter et 
al. (1992) also labelled the cysteine 302 amino acid residue using trans-4-(N,N-
dimethy I amino )annamaldehyde and 4-trans-(N ,N-dimethylamino) annamoy 1-
imidazole. 
Abriola et al. (1987, 1990) showed that glutamic acid 268, as well as cysteine 302, 
was labelled by bromoacetophenone, an active site directed reagent that 
irreversibly abolishes both the dehydrogenase and esterase activities. 
Circumstantial evidence for the involvement of serine 74 as the active site 
nucleophile has been obtained from labelling studies using the chromophoric 
substrate trans-4-(N,N-diethylamino)cinnamaldehyde (Loomes et al., 1990). 
1.8 ALDHEHYDE DEHYDROGENASE ACTIVE SITE 
1.8.1 Proposed reaction pathway 
Unlike many other dehydrogenases the detailed mechanism for the oxidation of 
substrate is not known. Initial kinetic studies with the horse liver enzyme lead to 
the conclusion that ALDH functioned with ordered binding and that NAD+ was 
the lead substrate. The rate limiting step for the enzyme was thought to be the 
acylaction step (Feldman & Weiner, 1972). It was also proposed that the active 
site should possess a general base to help in the deacylation step as illustrated in 
figure 1.2. 
Other investigators studying the enzyme from different species concluded that the 
NADH dissociation could be rate limiting. Figure 1.1 illustrates the proposed 
active site reaction pathway proposed by Weiner et al. (1995). 
Proposed ALDH active site reaction pathway 
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Figure I.I 
Model showing the reaction pathway for the ALDH catalysed oxidation of an aldehyde (Weiner et 
al., 1995). 
ALDH active site base 
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Figure 1.2 
General base facilitated deacylation of the acyl intermediate (Weiner et al., 1995). 
1.8.2 Esterase and dehydrogenase activity 
ALDH has been shown to possess, in addition to dehydrogenase activity, an 
esterase activity (Feldman & Weiner, 1972; Blackwell et al., 1983). Based on 
mechanistic considerations and inhibition studies, it was proposed that the 
oxidative and hydrolytic reactions catalysed by horse liver ALDH proceed via a 
common intermediate involving the active site cysteine (Feldman & Weiner, 
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1972). Kinetic arguments in support of a common active site have been presented 
(Duncan, 1985; Kitson, 1982, 1986; Loomes & Kitson 1986). 
Mutational analyses of the enzyme including serine 74 (Rout & Weiner, 1994) 
and cysteine 302 (Farres et al., 1995) as well as glutamate (Wang & Weiner, 
1995) all showed that there was a parallel loss of dehydrogenase and esterase 
activity. Therefore it appears that the two reactions catalysed by ALDH require 
the same active site components and occur at the same site (see section 1.9). 
However studies by Blackwell et al. (1983) indicate participation of separate sites 
in the oxidative and hydrolytic reactions catalysed by sheep liver cytosolic ALDH. 
This proposal was supported by chemical modification studies carried out by Tu 
& Weiner (1988), Deady et al. (1985) and Abriola & Pietruszko (1992). 
1.9 MUTAGENESIS STUDIES 
Information gained from kinetic and chemical modification studies (Hempel & 
Pietruszko, 1981; Tu & Weiner, 1988; Loomes et al., 1990), combined with the 
identification of highly conserved amino acid residues across the various forms of 
ALDH (Hempel et al., 1993), lead to numerous studies employing site-directed 
mutagenesis to further determine the components of the active site. 
Sections 1.9.2 and 1.9.3 overview the amino acid residues that have been altered 
by site-directed mutagenesis to determine whether they played a role in the ALDH 
active site. 
1.9.1 Conserved amino acid residues 
Sequence alignment of the primary sequences of all know ALDHs revealed that 
cysteine 302, glutamic acid 268, glutamic acid 399, lysine 272 and serine 471 
were the only residues with a potential catalytic function which are conserved 
1.9.2 
1.9.2.1 
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among all the know sequences (Hempel et al., 1993; von Bahr-Lindstrom et al. , 
1985). Refer to the appendix for a ALDH primary sequence alignment. 
Active site nucleophile 
Cysteine 
Labelling by various substrates and substrate analogues implicated the cysteine 
residues 49 and 302 as probable active site nucleophiles (von Bahr-Lindstrom et 
al., 1985; Kitson et al., 1991; Pietruszko et al., 1993). Sequence comparisons also 
demonstrated that cysteine 49, 301 and 302 where conserved across the various 
ALDH sequences and were therefore candidates for the active site nucleophile. 
Weiner et al. (1995) altered cysteine 302 and cysteine 49 in the recombinant rat 
liver class 2 ALDH. They showed that converting cysteine 49 to alanine did not 
affect the activity of the enzyme. In contrast however they reported that changing 
cysteine 302 to alanine lead to an enzyme void of catalytic activity (Weiner et al., 
1995). 
Cysteine 302 has been altered to serine in studies using both the class 1 and class 
2 forms of the ALDH enzyme (Weiner et al., 1995; Jones et al., 1995). This 
change lead to an oxygen being substituted for sulphur at the postulated active 
site. This alteration caused the mutant enzyme to have greatly reduced catalytic 
activity. Jones et al. (1995) also altered cysteine 302 to alanine in the 
recombinant human liver class 1 ALDH and concluded from their research that 
cysteine 302 was likely to be the active site nucleophile, in agreement the 
mutagenesis studies of the mitochondrial enzyme (Weiner et al., 1995; Jones et 
al., 1995). 
1.9.2.2 
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Serine 
Circumstantial evidence for the involvement of serine 74 as the active site 
nucleophile has been obtained from labelling studies (Loomes et al., 1990). 
Unlike cysteine 302, serine 74 is not a conserved residue in all species. 
Rout & Weiner (1994) found that the replacement of serine 74 by an alanine 
residue caused the class 2 enzyme to have a Vmax of just 10%. The fact that the 
enzyme still maintained some activity and that the residue was not highly 
conserved across species suggested that serine 74 was not the essential 
nucleophile in the active site (Rout & Weiner, 1994). Weiner et al. (1995) 
constructed the corresponding cysteine and threonine mutant enzymes in 
recombinant rat liver class 2 ALDH. They found that both of the expressed 
enzymes behaved like the alanine mutant. 
Active site base 
Histidine 
Histidine has been shown to be a general base catalyst in many enzymes including 
proteinases and dehydrogenases (Takahashi et al., 1981; Fersht, 1985; Weiner et 
al., 1985). The possibility of a histidine residue being involved in an acid base 
reaction was proposed by Weiner et al. (1991) however no direct evidence existed 
to suggest that the residue functioned in this capacity. Kinetic studies on horse 
liver mitochondrial ALDH which showed that a group with a pK., of 7 
(presumably histidine) maybe involved in the active site environment supported 
this proposal (Takahashi et al., 1981). 
Through chemical modification of the residue Weiner et al. (1985) demonstrated 
that histidine is not absolutely required for the enzyme to function. Attempts were 
made to chemically modify the residue with diethylpyrocarbonate but this 
modification only lead to partial inactivation of the enzyme (Weiner et al., 1985). 
1.9.3.2 
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Based on the companson of the known mammalian ALDH sequences both 
histidine 235 and histidine 29 were found to be highly conserved. The mutation 
of histidine 235 and histidine 29 to alanine demonstrated that these residues were 
not essential for catalytic activity and that they may not function as a general base 
in the deacylation step as originally suggested by Zheng & Weiner (1993). 
Instead both the highly conserved histidines may be involved in obtaining and 
maintaining the stable native structure of the enzyme (Zheng & Weiner, 1993). 
Glutamic acid 
On the basis of chemical modification studies it was postulated that glutamic acid 
268 was a component of the liver ALDH active site (Abriola et al., 1987, 1990; 
Pietruszko et al., 1991, 1993). Later it was found that all ALDHs had a conserved 
glutamate at position 268, supporting the suggestion that the residue could indeed 
be functioning as a component in the enzymes active site (Hempel et al., 1993). 
In human liver class 2 ALDH, the glutamic acid residue was mutated to aspartate, 
glutamine and lysine. The different mutations did not affect the ~ 1 values for 
NAD+ or propionaldehyde, but grossly affected the catalytic activity of the 
enzymes when compared to recombinantly expressed native enzyme. 
Furthermore both the dehydrogenase activity and esterase activity were essentially 
abolished when glutamate was changed to either aspartate, glutamine or lysine 
(Wang & Weiner, 1995). 
These results can be interpreted as implying that glutamic acid 268 may function 
as a general base necessary for the initial activation of the essential cysteine 
residue, rather than being involved in only the deacylation or hydride transfer step. 
Alternatively glutamate 268 could function as a component of a charge relay triad 
necessary to activate the nucleophilic residue. 
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1.10 TERTIARY STRUCTURE STUDIES OF THE ACTIVE SITE 
Since the completion of the research component the tertiary structure of the class 2 
ALDH was resolved by Steinmetz et al. (1997). From this research a chemical 
mechanism was suggested whereby glutamic acid 268 functions as a general base 
through a bound water molecule. The side amide nitrogen of asparagine 169 and 
the peptide nitrogen of cysteine 302 were found to be in a position to stabilise the 
oxygen present in the tetrahedral transition state prior to hydride transfer. The 
functional importance of glutamic acid 487 now appears to be due to indirect 
interaction of this residue with the substrate-binding site via arginine 264 and 
arginine 475 (Steinmetz et al., 1997). 
1.11 AIM OF THE INVESTIGATION 
The precise mechanism of action of ALDH has not been defined. Understanding 
the mechanism of action of the enzyme and the amino acid residues involved in 
the cofactor and substrates will provide valuable information for determining 
which metabolites are likely to be natural substrates for the enzyme. 
During the research component of this thesis, studies on the tertiary structure of 
ALDH where not sufficiently advanced to suggest which amino acid residues 
where important in catalysis (Baker et al., 1995; Hurley & Weiner, 1992). 
Therefore the primary aim of this project was to use SDM to help define if the 
amino acid lysine 272 was important for enzymatic activity. 
Lysine 272 is another potential base that is totally conserved and therefore a 
strong candidate for an important role in the catalytic activity of ALDH. 
Subsequent comparisons of the properties of the mutants obtained with those of 
the wild type enzyme will help to determine the importance of the residues in the 
enzyme's structure and function. 
